Ackroyd SA, Huang ES, Kurnit KC, et al. - Researchers used a Markov model to ascertain the cost effectiveness of pembrolizumab/lenvatinib (P/L) vs standard-of-care carboplatin/paclitaxel (C/T) as first-line systemic therapy for patients suffering from advanced/recurrent endometrial cancer. For patients whose tumors were either microsatellite stable (MSS) or have high microsatellite instability (MSI-high), treatment outcomes were simulated. For analysis, a healthcare sector perspective was employed. Findings in the MSS model revealed both increased costs and worsened outcomes in relation to use of P/L for first-line therapy for advanced or recurrent endometrial cancer vs C/T. Results in the MSI-high model demonstrated improved survival and quality-adjusted life years in relation to treatment with P/L vs C/T, however, P/L failed to be a cost-effective option at the current cost of the drugs.